

# Tackling metabolic disorders with non-coding RNAs



Resalis Therapeutics' transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease.

2018

Researcher at Harvard Medical School discover the role of miR-22 in metabolism control

2021

Resalis is founded with 10M € seed from trusted investors



### Leadership



Alessandro Toniolo  
Chief Executive Officer




Riccardo Panella  
CSO & Founder



Sakari Kauppinen  
CTO & Founder

### Board of Directors




Pietro Puglisi (Chairman), Michael Hodges, Antonio Leone




RES-010 is a miR-22 inhibitor based on LNA chemistry and a mix-mer design to optimize stability and reduce toxicity.

2022

Resalis' academic and non-academic collaborations reveal more details on RES-010 MoA including the additive effect on GLP-1 RA therapy



### Trend of >20% weight loss responders



2023

Resalis successfully moved to NHP and started working with world class CRO to prepare for clinical development

2024

IND/CTA filing and Phase 1 execution



2028

Multiple exit options